Grufity logoGrufity logo

Surface Oncology Inc Stock Research

SURF

0.72USD+0.03(+4.38%)Market Closed

Market Summary

USD0.72+0.03
Market Closed
4.38%

SURF Stock Price

SURF RSI Chart

SURF Valuation

Market Cap

43.5M

Price/Earnings (Trailing)

-0.68

Price/Sales (Trailing)

1.45

EV/EBITDA

0.19

Price/Free Cashflow

-0.72

SURF Price/Sales (Trailing)

SURF Profitability

EBT Margin

-2920.92%

Return on Equity

-68.08%

Return on Assets

-39.76%

Free Cashflow Yield

-137.96%

SURF Fundamentals

SURF Revenue

Revenue (TTM)

30.0M

Revenue Y/Y

-100%

Revenue Q/Q

-100%

SURF Earnings

Earnings (TTM)

-63.6M

Earnings Y/Y

11.3%

Earnings Q/Q

8.21%

Price Action

52 Week Range

0.603.17
(Low)(High)

Last 7 days

4.2%

Last 30 days

-15.3%

Last 90 days

-14.0%

Trailing 12 Months

-74.6%

SURF Financial Health

Current Ratio

7.94

SURF Investor Care

Shares Dilution (1Y)

29.00%

Diluted EPS (TTM)

-1.14

Peers (Alternatives to Surface Oncology)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
125.3B
26.3B
-2.75% 3.76%
19.12
4.76
1.32% 11.18%
99.6B
27.3B
-8.96% 41.01%
21.68
3.65
-0.09% -26.23%
58.4B
19.3B
-12.76% 1.00%
6.99
3.03
4.29% -31.47%
38.3B
10.2B
-9.67% 32.94%
12.57
3.76
-7.36% 95.80%
MID-CAP
9.1B
1.5B
-9.09% 3.35%
58.87
6.11
31.34% 72.43%
3.2B
108.5M
-21.10% -19.55%
-9.78
29.38
122.90% -12.19%
2.5B
60.9M
-18.47% -36.46%
-8.76
41.55
17.51% 22.00%
2.1B
107.9M
22.95% 67.45%
-4.29
19.27
54.84% 17.36%
SMALL-CAP
1.2B
112.0M
-14.86% -46.41%
-4.63
11.04
-70.76% -603.77%
1.1B
7.0M
-22.18% 24.65%
-7.11
158.97
131.81% -45.39%
541.9M
96.3M
-12.99% -82.24%
-1.92
5.63
72.44% -32.79%
513.7M
2.0B
-39.67% -92.01%
-0.78
0.26
72.89% 62.27%
355.3M
111.3M
-30.55% -58.78%
-1.85
3.19
0.54% -7.86%
101.4M
159.0K
-16.47% -82.96%
-0.97
637.62
-86.46% -64.56%
25.1M
-
94.03% -77.12%
-0.31
3.21
0.51% -185.61%

Financials for Surface Oncology

Income Statement (Last 12 Months)
Description(%) Q/Q2022Q42022Q32022Q22022Q12021Q4
Revenue-0.5%30,000,00030,155,00020,999,00011,843,0002,687,000
Operating Expenses-2.5%91,869,00094,213,00091,199,00085,678,00078,700,000
  S&GA Expenses-5.0%24,866,00026,175,00026,018,00026,026,00025,128,000
  R&D Expenses-1.5%67,003,00068,038,00065,181,00059,652,00053,572,000
EBITDA0.4%-74,506,000-74,773,000---
EBITDA Margin0.4%-27.73-27.83---
EBT Margin0%-29.21-29.21---
Interest Expenses7.4%3,146,0002,929,0002,521,0002,204,0002,546,000
Net Income4.1%-63,586,000-66,304,000-62,957,000-56,725,000-78,485,000
Net Income Margin3.6%-2.12-2.20-23.43--
Free Cahsflow-11.4%-60,049,000-53,928,000-50,352,000-67,102,000-
Balance Sheet
(In Millions)
* denotes actual numbers (not divided by Millions)
Description(%) Q/Q2022Q42022Q32022Q22022Q12021Q4
Assets-12.0%160182194218191
  Current Assets-14.0%129150162184157
    Cash Equivalents-21.8%51.0065.0075.0066.0056.00
  Net PPE-1.2%5.005.005.005.006.00
Liabilities-3.3%67.0069.0068.0071.0072.00
  Current Liabilities-9.6%16.0018.0020.0020.0020.00
Shareholder's Equity-17.2%93.00113126147119
  Retained Earnings-11.7%-204-183-159-134-140
  Additional Paid-In Capital0.5%299297287282260
Accumulated Depreciation-8.00----
Shares Outstanding0.1%61.0061.0055.0054.0047.00
Cashflow (Last 12 Months)
(In Thousands)
Description(%) Q/Q2022Q42022Q32022Q22022Q12021Q4
Cashflow From Operations-11.0%-59,552-53,655-50,086-66,947-62,344
  Share Based Compensation-4.3%7,2237,5477,8258,0318,546
Cashflow From Investing316.0%22,7575,471-3,032-16,153-99,252
Cashflow From Financing-39.6%31,66052,43244,60748,23142,500

Risks for SURF

What is the probability of a big loss on SURF?

95.0%


Probability that Surface Oncology stock will be more than 20% underwater in next one year

94.6%


Probability that Surface Oncology stock will be more than 30% underwater in next one year.

93.4%


Probability that Surface Oncology stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does SURF drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Surface Oncology was unfortunately bought at previous high price.

Drawdowns

Returns for SURF

Cumulative Returns on SURF

-32.9%


3-Year Cumulative Returns

Which funds bought or sold SURF recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2023-02-21
MACQUARIE GROUP LTD
unchanged
-
-77,000
287,000
-%
2023-02-15
JANE STREET GROUP, LLC
new
-
107,887
107,887
-%
2023-02-15
Belvedere Trading LLC
new
-
2,338
2,338
-%
2023-02-14
TWO SIGMA ADVISERS, LP
reduced
-21.8
-17,464
28,536
-%
2023-02-14
TWO SIGMA SECURITIES, LLC
new
-
12,701
12,701
-%
2023-02-14
SUSQUEHANNA INTERNATIONAL GROUP, LLP
added
108
15,848
40,848
-%
2023-02-14
Bank of New York Mellon Corp
reduced
-26.75
-78,438
108,562
-%
2023-02-14
Laurion Capital Management LP
unchanged
-
-146,372
545,628
-%
2023-02-14
DAFNA Capital Management LLC
reduced
-28.82
-501,940
642,060
0.18%
2023-02-14
MARSHALL WACE, LLP
reduced
-46.4
-125,039
90,961
-%

1–10 of 44

Latest Funds Activity

Are funds buying SURF calls or puts?
Calls
Puts
Are funds bullish or bearish(Calls - Puts)?
Net Call Options
No. of funds that own SURF
No. of Funds

Surface Oncology News

Nasdaq

Walgreens (WBA) to Report Q2 Earnings: What's in the Cards?.

Nasdaq,
47 hours ago

ETF Daily News

Insider Monkey

InvestorPlace

Schedule 13G FIlings of Surface Oncology

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 13, 2023
ecor1 capital, llc
6.5%
3,924,713
SC 13G/A
Jan 31, 2023
atlas venture fund ix, l.p.
4.87%
2,945,453
SC 13G/A
May 09, 2022
blackrock inc.
4.6%
2,502,271
SC 13G
Mar 14, 2022
ecor1 capital, llc
9.9%
4,653,000
SC 13G
Feb 10, 2022
eli lilly & co
3.5%
1,593,997
SC 13G/A
Feb 09, 2022
ark investment management llc
11.54%
5,326,127
SC 13G/A
Feb 09, 2022
fmr llc
-
0
SC 13G/A
Feb 04, 2022
blackrock inc.
5.6%
2,562,685
SC 13G
Jan 25, 2022
atlas venture fund ix, l.p.
6.38%
2,945,453
SC 13G/A
Jul 09, 2021
ark investment management llc
10.31%
4,476,420
SC 13G/A

SURF Fair Value

Recent SEC filings of Surface Oncology

View All Filings
Date Filed Form Type Document
Mar 09, 2023
10-K
Annual Report
Mar 09, 2023
8-K
Current Report
Mar 09, 2023
S-8
Employee Benefits Plan
Mar 03, 2023
4
Insider Trading
Mar 03, 2023
4
Insider Trading
Mar 03, 2023
4
Insider Trading
Mar 03, 2023
4
Insider Trading
Mar 03, 2023
4
Insider Trading
Mar 03, 2023
4
Insider Trading
Feb 13, 2023
SC 13G/A
Major Ownership Report

Latest Insider Trading transactions for SURF

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2022-08-03
FEES JESSICA
sold
-10,285
1.72
-5,980
chief financial officer
2022-08-03
ROSS ROBERT W.
sold
-18,221
1.72
-10,594
chief executive officer
2022-08-03
RATH HENRY C.
sold
-9,762
1.72
-5,676
chief business officer
2022-08-03
Palombella Vito J.
sold
-7,676
1.72
-4,463
chief scientific officer
2022-08-03
ONEILL ALISON
sold
-7,676
1.72
-4,463
chief medical officer
2022-03-01
FEES JESSICA
acquired
-
-
38,000
chief financial officer
2022-03-01
ONEILL ALISON
acquired
-
-
38,000
chief medical officer
2022-03-01
ROSS ROBERT W.
acquired
-
-
56,000
chief executive officer
2022-03-01
RATH HENRY C.
acquired
-
-
38,000
chief business officer
2022-03-01
Palombella Vito J.
acquired
-
-
38,000
chief scientific officer

1–10 of 50

Robert W. Ross
70
Surface Oncology, Inc., a clinical-stage immuno-oncology company, engages in the development of cancer therapies in the United States. The company develops various antibodies that include NZV930, a fully human immunoglobulin isotype G4 monoclonal antibody for the production of extracellular adenosine; SRF617, a fully human IgG4 monoclonal antibody that inhibits CD39 enzymatic activity for the production of adenosine and the breakdown of adenosine triphosphate; SRF388 targeting interleukin 27; GSK4381562, an antibody targeting CD112R, an inhibitory protein expressed on natural killer and T cells; and SRF114 targeting the chemokine receptor CCR8. Surface Oncology, Inc. has a license agreement with GlaxoSmithKline Intellectual Property (No. 4) Limited to develop, manufacture, and commercialize antibodies that targets SRF813; and license agreement with Vaccinex, Inc. to develop, manufacture, and commercialize antibodies, which targets SRF114. The company was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

SURF Income Statement

2022-12-31
Consolidated Statements of Operations and Comprehensive Income (Loss) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Statement of Comprehensive Income [Abstract]   
Collaboration revenue - related party$ 0$ 0$ 38,592
License-related revenue30,0002,68787,570
Total revenue30,0002,687126,162
Operating expenses:   
Research and development67,00353,57241,018
General and administrative24,86625,12823,558
Total operating expenses91,86978,70064,576
Income (loss) from operations(61,869)(76,013)61,586
Interest expense(3,146)(2,546)(2,855)
Other income, net1,42974606
Net income (loss)$ (63,586)$ (78,485)$ 59,337
Net income (loss) per share - basic (in dollars per share)$ (1.14)$ (1.77)$ 1.67
Weighted average commons shares outstanding—basic (shares)55,761,38644,243,31735,545,121
Net income (loss) per share - diluted (in dollars per share)$ (1.14)$ (1.77)$ 1.57
Weighted average common shares outstanding—diluted (shares)55,761,38644,243,31738,141,793
Comprehensive income (loss):   
Net income (loss)$ (63,586)$ (78,485)$ 59,337
Other comprehensive loss:   
Unrealized loss on marketable securities, net of tax(794)(221)(103)
Comprehensive income (loss)$ (64,380)$ (78,706)$ 59,234

SURF Balance Sheet

2022-12-31
Consolidated Balance Sheets - USD ($)
$ in Thousands
Dec. 31, 2022
Dec. 31, 2021
Current assets:  
Cash and cash equivalents$ 50,910$ 56,045
Marketable securities73,91398,104
Prepaid expenses and other current assets4,3173,197
Total current assets129,140157,346
Property and equipment, net4,8665,651
Operating lease right-of-use asset24,30725,870
Restricted cash1,5951,595
Other assets2385
Total assets159,910190,847
Current liabilities:  
Accounts payable2561,550
Accrued expenses and other current liabilities10,21413,089
Operating lease liability5,7905,384
Total current liabilities16,26020,023
Operating lease liability, non-current24,66226,909
Convertible note payable, non-current25,58525,015
Total liabilities66,50771,947
Commitments and contingencies
Stockholders’ equity:  
Preferred stock, $0.0001 par value per share; 5,000,000 shares authorized    at December 31, 2022 and December 31, 2021; no shares    issued and outstanding at December 31, 2022 and December 31, 202100
Common stock, $0.0001 par value; 150,000,000 authorized at December 31, 2022    and December 31, 2021; 60,578,956 and 46,958,776 shares issued and    outstanding at December 31, 2022 and December 31, 2021, respectively65
Additional paid-in capital298,741259,859
Accumulated other comprehensive loss(1,015)(221)
Accumulated deficit(204,329)(140,743)
Total stockholders’ equity93,403118,900
Total liabilities and stockholders’ equity$ 159,910$ 190,847